Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as ‘resistance’, is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3–26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60% were women, and over 85% of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such ‘strong’ protected platelets.

Keywords:
Platelets, Aspirin, Stroke, Triglycerides
1.
Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ: PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195–202.
2.
Boldt J, Huttner I, Suttner S, Kumle B, Piper SN, Berchthold G: Changes of haemostasis in patients undergoing major abdominal surgery – is there a difference between elderly and younger patients? Br J Anaesth 2001;87:435–440.
3.
Halil M, Cankurtaran M, Yavuz BB, Ulger Z, Piskinpasa S, Gedik A, Haznedaroglu IC, Kirazli S, Ariogul S: Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007;41:41–45.
4.
Assadian A, Lax J, Meixner-Loicht U, Hagmuller GW, Bayer PM, Hubl W: Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007;45:1142–1147.
5.
Hobikoglu GF, Norqaz T, Aksu H, Ozer O, Erturk M, Destequl E, Akyuz U, Unal Dia S, Narin A: The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007;23:201–206.
6.
Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331–2336.
7.
Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175–178.
8.
Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD: Aspirin response and failure in cerebral infarction. Stroke 1993;24:345–350.
9.
Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD: Failure of aspirin treatment after stroke. Stroke 1994;25:275–277.
10.
Karepov VG, Tolpina GI: Hyperlipidemia and aspirin resistance in post-stroke patients. 1st International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention, Paris, 2006.
11.
Coma-Canella I, Velasco A, Castano S: Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005;101:71–76.
12.
Gum PA, Kottke-Marchant R, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230–235.
13.
Hamsten A: Lipids as a coronary risk factor: analysis of hyperlipidaemias. Postgrad Med J 1993;69(suppl 1):S8–S11.
14.
Karepov VG: Aspirin resistance, hyperlipidemia and secondary stroke prevention. Int J Stroke 2006;1(suppl 1):72–73.
15.
Porto I, Leone AM, Nanni L, Sciahbasi A, De Vita M, Lanza GA, Andreotti F: Interplay of platelet polymorphisms, risk factors, and von Willebrand factor in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease. Blood Coagul Fibrinolysis 2005;16:97–104.
16.
Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, Koylan N, Bugra Z, Meric M, Nisanci Y: Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007;18:461–465.
17.
Bornstein NM, Aronovich BD, Karepov VG, Gur AY, Treves TA, Oved M, Korczyn AD: The Tel Aviv Stroke Registry: 3,600 consecutive patients. Stroke 1996;27:1770–1773.
18.
Haubelt H, Anders C, Hellstem P: Can platelet function tests predict clinical efficacy of aspirin? Semin Thromb Hemost 2005;31:404–410.
19.
Gurbel PA, Blinden KP, Di Chiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation 2007;115:3156–3164.
20.
Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) – its relation to metabolic control. Thromb Res 2004;113:101–113.
21.
Durrington PN: Diabetes, hypertension and hyperlipidaemia. Postgrad Med J 1993;69(suppl 1):S18–S29.
22.
Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001–1005.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.